The aim of this retrospective study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic PEG-G-CSF support for pretreated NSCLC in Japanese clinical practice. This evidence concerns the gene CSF3 and non-small cell lung carcinoma.